Patent 7998475 was granted and assigned to Oxitec on August, 2011 by the United States Patent and Trademark Office.
Undesirable genetic traits, such as resistance to toxin, can be inhibited or reversed by introducing sexually compatible individuals substantially homozygous for the sensitive allele, such as the wild type, into the target population.